Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Werewolf Therapeutics Inc. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct examiners and the distinct art units. LI, RUIXIANG is the busiest examiner, holding 1 busiest examiner pending action. This distribution shows that the 2 pending office actions are handled by different examiners rather than being concentrated.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LI, RUIXIANG | 1 | 59.5% | +18.7% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 57.4% | +30.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440816 | INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPY | LI, RUIXIANG | — |
| 17741275 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18440816 | INDUCIBLE CYTOKINE PRODRUG AND PD-1/PD-L1 COMBINATION THERAPY | LI, RUIXIANG | 1674 | §103§112DP | Non-Final OA | — | Pending | Feb 13, 2024 |
| 17741275 | ACTIVATABLE CYTOKINE POLYPEPTIDES AND METHODS OF USE THEREOF | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §103 | Final Rejection | — | Pending | May 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialWerewolf Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Ruixiang Li has the most, with 1 of Werewolf Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
